Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Plasma levels of endothelin (ET), vasoconstrictor peptide released from vascular endothelial cells, have been measured by radioimmunoassay in 48 patients with NIDDM and 20 healthy subjects. The plasma ET concentrations were found to be greatly elevated in the patients with diabetes compared with the healthy subjects (P < 0.001). We also find that the plasma levels of ET were higher in diabetic patients with complication of diabetes mellitus than in those without complication (P < 0.02). The elevated ET levels were related to hypertension and/or diabetic angiopathy. There were no significant correlations between plasma ET concentrations and blood glucose, HbA1 et al. In diabetic patients elevated ET levels may play a pathophysiological role in the development of diabetic complication.
Zhonghua Nei Ke Za Zhi 1994 Jul
PMID:[The relationship between the plasma levels of endothelin and angiopathy in diabetic patients]. 786 43

The clinical and echocardiographic variables related to postinfarction angina were evaluated in 54 patients with acute myocardial infarction. All patients underwent 2D echocardiography at 2-3 weeks after infarction. Wall motion analysis was quantified with a wall motion score index (WMSI) based on 16 left ventricular wall segments. Among the 54 patients with acute myocardial infarction 23 (42.6%) had early postinfarction angina. Multiple regression analysis demonstrated no significant difference between the patients with and without postinfarction angina in age, sex, location of infarction, Killip classification, previous angina, hypertension, hyperlipidemia, diabetes mellitus, creatine kinase level and left ventricular ejection fraction. In comparison with patients without postinfarction angina, patients with postinfarction angina had higher WMSI. It indicates that postinfarction angina appears to be related more to myocardial ischemia rather than to the infarct of myocardium.
Zhonghua Nei Ke Za Zhi 1994 Aug
PMID:[Analysis of risk factors in postinfarction angina]. 788 38

Eighty one elderly patients with paroxysmal atrial fibrillation were studied with respect to clinical features, effect of antiarrhythmic drugs and prognosis. 35 (43.2%) patients were associated with coronary artery disease and/or hypertension, while 23 (28.4%) patients had no other cardiovascular diseases. The latter condition was significantly less in patients over 60 years old when they had the first paroxysmal attack. Atrial fibrillation became permanent in 18 (22.2%) patients. Left atrial enlargement and abnormal cardiac function were significant independent factors affecting the type of atrial fibrillation. During an observation period of 12-84 months, the incidence of cerebral embolism and cardiac death were 6.1% and 4.9% respectively in all cases. We did not find that the prognosis of patients was affected by the types of atrial fibrillation.
Zhonghua Nei Ke Za Zhi 1994 Aug
PMID:[Clinical features and prognosis of paroxysmal atrial fibrillation in the elderly]. 788 39

Swan-Ganz catheterization, blood gas analysis, pulmonary function tests and two-dimensional echocardiography were performed in 10 patients with pulmonary heart disease and the effects of nifedipine were then observed. Mean pulmonary artery pressure (mPAP) correlated significantly to PaO2. PaO2 may be a useful parameter for predicting mPAP. Continuous oxygen breathing can correct hypoxemia, prevent and alleviate pulmonary artery hypertension (PAH). After using nifedipine, PaO2 and blood pressure of systemic circulation decreased significantly, while pulmonary physiological shunt increased and pulmonary artery pressure did not decrease. As a consequence, the use of nifedipine to treat pulmonary heart disease and PAH is not advocated.
Zhonghua Nei Ke Za Zhi 1994 Jan
PMID:[Hemodynamic studies of pulmonary heart diseases and the effects of nifedipine]. 804 82

Anemia is one of the serious complications of chronic renal failure, therapy with recombinant human erythropoietin (r-HuEPO) can correct such anemia officiently. For most patients, the initial dose of r-HuEPO is 100U/kg, by intravenously or subcutaneous, three times a week. After 6 weeks of treatment, Hb could increase to 100g/L, and Hct to above 0.33-0.35. Then 500/kg 3 time a week can be used as maintaining dose. 4 patients need maintaining dose of 150U/kg, for pulmonary infection, poor nutrition, and poor iron supply. Therefore, during the treatment, iron folie acid and Vit B12 should be applied sufficiently and treat the infection effectively with the increasing of Hb and Hct, 2/3 of the patients have hypertension which can be controlled with medication. If there is thrombosis in the dialyzer, the dose of heparin should be increased. The patients on r-HuEPO should be dialysised sufficiently to prevent hyperkalemia.
Zhonghua Nei Ke Za Zhi 1994 Feb
PMID:[The observation of therapy of anemia in chronic renal failure with recombinant human erythropoietin]. 807 Feb 95

The effects of different dosage of PGE1 on hemodynamics, oxygen delivery (DO2), oxygen consumption (VO2) and hemorheology in patients with pulmonary arterial hypertension (PAH) were investigated. In group 1, 10 cases were treated with PGE1 at a dosage of 20ng/kg.min-1, It was found that pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) decreased by 23.3% and 38.7% respectively, CI and DO2 increased significantly; blood viscosity decreased significantly, but mean arterial pressure (MAP) and PaO2 were not affected. The side effects at such a dosage included flush of skin, headache and malaise. In group 2, 8 of the 10 cases were treated with PGE1 at a dosage of 40ng/kg.min-1. It was found that mPAP and PVR decreased by 22% and 40.4% respectively, CI increased significantly, MAP, systemic vascular resistance (SVR) and PaO2 decreased significantly while DO2 and VO2 changed slightly. The side effects at this dosage consisted of those occurring at the dosage of 20ng/kg.min-1 as well as hypotension and tachycardia. These results showed that PGE1 at a dosage of 20ng/kg.min-1 is effective, well-tolerated and yields less side effects.
Zhonghua Nei Ke Za Zhi 1993 Sep
PMID:[Effects of different dosage of PGE1 in pulmonary arterial hypertension]. 811 40

We analysed fasting serum insulin levels and its correlation with common internal medical diseases in 91 cases with obesity (BMI > 24) and that in 76 nonobese cases. The mean fasting serum insulin level in obese group was higher significantly than that in nonobese group (P < 0.001). The incidences of hypertension, coronary heart disease, cerebrovascular disease, non-insulin-dependent diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, combined hyperlipidemia and serum low level of HDL-C in obese group were also higher significantly than that in nonobese group (P < 0.05 and < 0.01 respectively). The main cause of many medical diseases coexisted with obesity is hyperinsulinemia. We think that the first choice of therapy to this kind of diseases should be to reduce the body weight and to decrease the insulin resistance.
Zhonghua Nei Ke Za Zhi 1993 Oct
PMID:[Hyperinsulinemia in obesity and diseases of internal medicine]. 815 34

Esophageal investigation was performed successfully in 52 patients who were initially suspected of suffering from angina pectoris, but the pain was subsequently shown to be not of cardiac origin by radionuclide myocardiac perfusion and (or) coronary angiography in 74% of cases, and by EKG and poor response to anti-angina therapy in 26% of the cases. In 82.7% of the patients the diagnosis was gastroesophageal reflux disease (GERD), in 3.8% Nutcracker esophagus, and in 5.8% lower esophageal sphinctor hypertension. In the remaining 7.7% the diagnosis was unknown. In 43 patients with GERD, gastroesophageal reflux (GER) investigation showed GER symptoms in 61.5%, reflux esophagitis was confirmed with endoscopy in 45.3%. Abnormal esophageal manometry was found in 53.8%, positive provocative test in 42.9%, excessive radionuclide GER in 50%, and increased duration of hyperacidity in 57.1%. However, a combined study of the procedures mentioned above showed that the diagnosis was consistent with GERD in 82.3% of the patients. Chest pain was completely relieved in 34% of the cases and significantly relieved in 50%. No response was ilicited in 16% of the cases after 1-2 weeks of anti-reflux therapy. It is found that chest pain induced by GERD is very common, esophageal endoscopy and motor studies are helpful in the diagnosis of GERD and other esophageal motor diseases, and anti-reflux therapy is a reliable measure when a patient complains of unknown chest pain and GER symptoms.
Zhonghua Nei Ke Za Zhi 1993 May
PMID:[Diagnosis and treatment of angina-like chest pain in 52 cases]. 826 55

Subcutaneous (s.c.) administration of recombinant human erythropoietin (rHuEPO) has been proven to be effective in anemia of predialysis patients with chronic renal failure (CRF). However, the optimal dosage and frequency of administration have not been established. We use low dose (< 100U.kg-1.w-1) of s.c. rHuEPO to treat renal anemia in two groups (group A: n = 18, twice a week; group B; n = 14, once a week) of nondialytic CRF patients. Hb and Hct gradually increased 1-3 months aftes rHuEPO treatment in the two groups. The incidence of hypertension, one of the main side effects, was lower (4/18 in Group A, 4/14 in Group B) than that reported in the literature. These results showed that either twice weekly or once weekly s.c. injection of low dose rHuEPO is effective and there will be less side effects treating predialysis patients with CRF.
Zhonghua Nei Ke Za Zhi 1993 Jul
PMID:[The effect of low doses of recombinant human erythropoietin on renal anemia in predialysis patients with chronic renal failure]. 827 19

Recombinant human erythropoietin (r-HuEPO) was administered in 68 dialyzed patients (32 on acetate hemodialysis, 24 bicarbonate hemodialysis and 12 on hemo-filtration). The mean initial Hb 52.7 +/- 8.0g/L, Ht 19.4 +/- 2.2%, serum ferritin > 100ng/L. Each patients received r-HuEPO intravenously, at the dose of 300U/Kg/w for 6.2 +/- 4.3 months. Target range: Hb 100-120g/L, Ht 30-35%. After r-HuEPO treatment, blood transfusion was not needed for any of the patients, anemia was ameliorated with increase of Hb and Ht levels. It was found that the minimum effective dose of the r-HrEPO was 150-300U/Kg/w. We conclude that r-HuEPO is effective as treatment for the anemia of dialyzed patients. However, hypertension, clotted dialyzers and dialysis access thromboses were been developed in some patients after correction of anemia. There is now a general consensus that these side effects may be minimized if r-HuEPO is initially given in small doses with increments to avoid a too rapid correction of the anemia.
Zhonghua Nei Ke Za Zhi 1993 Feb
PMID:[Clinical studies of recombinant human erythropoietin in patients on long-term dialysis]. 840 23


<< Previous 1 2 3 4 5 6 7 Next >>